Related Experiment Video
Updated: May 4, 2026
08:57
Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
Published on: March 26, 2015
29.7K
How to treat tumefactive demyelinating disease?
Volker Siffrin1, Wibke Müller-Forell, Harald von Pein
1Department of Neurology, Johannes Gutenberg University Mainz, Germany.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|December 19, 2013
Summary
Tumefactive demyelinating lesions, mimicking glioma, present treatment challenges. Early aggressive immunosuppression may prevent irreversible disability from these rare multiple sclerosis subtypes.
Area of Science:
- Neuroimmunology
- Neuropathology
Background:
- Tumefactive demyelinating lesions (TDL) are rare, often mimicking glioma.
- These lesions can occur in multiple sclerosis or as an isolated entity.
Observation:
- A patient with a relapsing unifocal TDL initially responded to steroids.
- Subsequent relapse led to incomplete recovery despite immunosuppression, with further deterioration.
Findings:
- Maximal immunosuppression eventually halted inflammatory activity in the TDL.
- Delayed, escalated treatment resulted in irreversible tissue damage and disability.
Implications:
- Current treatment guidelines for TDL are lacking.
- Early, aggressive induction therapy may be crucial for rare, disabling TDL subtypes.
- This case highlights the need for revised treatment strategies for tumefactive demyelinating lesions.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:28Diphtheria
175
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
175
01:27Tumor Immunotherapy
2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K